Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialoglycotope CA6 is a tumor-associated carbohydrate antigen found on the Mucin-1 (MUC1) protein. It arises from aberrant glycosylation of MUC1 in cancer cells, specifically a sialic acid-dependent glycoepitope recognized by the monoclonal antibody DS6. CA6 is highly expressed in several carcinomas, including breast, ovarian, lung, bladder, pancreas, and cervix, making it an attractive target for cancer therapy.
Antibody-drug conjugate (ADC) mediated cytotoxicity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialoglycotope CA6 (CA6).